[Chem. Pharm. Bull.]
34(10)4394—4399(1986)

Porcine Pancreatic Prokallikrein. IV. N-Terminal Amino Acid Sequences of Prokallikrein B and the Kallikrein Generated from It by the Action of Trypsin

KAZUYUKI KIZUKI,* HIROSHI MURAKAMI, MASAHARU HIRATSUKA,
MASAFUMI KAMADA and HIROSHI MORIYA

*Department of Biochemistry, Faculty of Pharmaceutical Sciences,
Science University of Tokyo, 12, Ichigaya-Funakawara-machi,
Shinjuku-ku, Tokyo 162, Japan*

(Received May 26, 1986)

Porcine pancreatic prokallikreins A and B were separately highly purified by water extraction in the presence of various protease inhibitors, ammonium sulfate salting-out fractionation, anion-exchange chromatography, immunoaffinity chromatography on an anti-porcine pancreatic kallikrein B antibody immobilized Sepharose 4B column and gel filtration on Sephacryl S-200. The specific activities of the final prokallikreins A and B preparations were 75.0 and 79.4 EU/ A_{280} (when assayed after activation with trypsin), respectively, and the prokallikrein B preparation showed a single band on the sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

The N-terminal amino acid sequence of prokallikrein B was H-Ala-Pro-Pro- and that of kallikrein B'', which is the kallikrein generated from prokallikrein B by the action of trypsin, was H-Ile-Ile-Gly-Gly-. The latter sequence agreed with that of the A-chain of kallikrein B, which is the kallikrein obtained from the autolyzed pancreas.

Keywords—kallikrein-kinin system; porcine pancreatic kallikrein; prokallikrein; tissue kallikrein; amino acid sequence; trypsin

Kallikrein in porcine pancreas is considered to exist mainly as its inactive form "prokallikrein" and to be activated to its functional form "kallikrein" by the action(s) of protease(s) in the pancreas or body fluid. However, several different forms of kallikrein generated from prokallikrein have been reported, *i.e.*, single-polypeptide-chain kallikrein (α -kallikrein), two-chain kallikrein (β -kallikrein) and three-chain kallikrein (γ -kallikrein).^{1,2} In order to elucidate the physiological and/or pathological significance of tissue kallikrein in the body, investigations to identify the enzyme(s) involved in the activation of prokallikrein in the body and to clarify the mechanism of activation of prokallikrein are very important.

The present paper deals with the isolation of porcine pancreatic prokallikreins A and B and the N-terminal amino acid sequence analyses of prokallikrein B and kallikrein B'' generated from it by the action of trypsin.

Materials and Methods

Materials—Fresh porcine pancreas was obtained from a slaughterhouse and stored at -25°C until required. The authentic phenylthiohydantoin (PTH)-amino acids were purchased from Pierce Chemical Co. (Rockford, IL., U.S.A.). Trypsin from porcine pancreas (type IX) and trypsin inhibitor from soybean (type I-S) (SBTI) from Sigma Chemical Co. (St. Louis, Mo., U.S.A.) were used for activation and the assay of prokallikrein. Kallikrein B'' (105.1 EU/ A_{280}) purified previously² was also used. Other reagents used were of guaranteed grade or the same as those mentioned in our previous papers.^{3,4}

Esterolytic Activity Assay—Esterolytic activity towards *N* $^{\alpha}$ -benzoyl-L-arginine ethyl ester (BzArgOEt) was measured photometrically as a kallikrein assay, and the activity was expressed in esterase units (EU). One EU is the

amount of enzyme that can hydrolyze 1 μ mol of BzArgOEt per min at 25 °C and pH 8.0. The amount of prokallikrein was determined in the same way as that mentioned in our previous paper, namely the amount of prokallikrein was estimated and expressed as EU after activation with trypsin.³⁾

Preparation of Anti-Porcine Pancreatic Kallikrein Antibody Immobilized Sepharose 4B Column—Kallikrein B was purified from autolyzed porcine pancreas⁵⁾ and was used for the preparation of anti-porcine pancreatic kallikrein B rabbit serum. The anti-porcine pancreatic kallikrein B rabbit serum obtained by the same procedures as mentioned in our previous paper⁴⁾ (total 4370 A_{280}) was diluted 2-fold and ammonium sulfate was added to it. The precipitate between 0–40% saturation was collected by centrifugation (7000 *g*, 30 min at 4 °C). The precipitate was dissolved in distilled water and dialyzed against 0.0175 M phosphate buffer, pH 8.0. Then, the dialysate was applied to a diethyl aminoethyl (DEAE)-cellulose column (2.2 $\times$ 25.0 cm) equilibrated with the same buffer and the non-adsorbed fraction (total 1064 A_{280}) was pooled and used for preparation of anti-porcine pancreatic kallikrein antibody-immobilized Sepharose 4B according to the method of Cuatrecasas.⁶⁾ The amount of immobilized protein was 2.54 mg/ml of Sepharose 4B gel.

Sodium Dodecyl Sulfate (SDS)-Polyacrylamide Gel Electrophoresis—This was carried out as described by Laemmli.⁷⁾ Samples were treated with or without 5% (v/v) 2-mercaptoethanol (2-ME) in 0.0625 M Tris-HCl buffer, pH 6.8, containing both 2% (w/v) SDS and 6% (v/v) glycerol for 3 min at 100 °C. After being fixed with 12.5% (w/v) trichloroacetic acid, proteins were stained with Coomassie brilliant blue R-250 dissolved in MeOH-AcOH-H₂O (9:2:9, v/v).

Analysis of N-Terminal Amino Acid Sequence—The N-terminal amino acid sequences of prokallikrein B and kallikrein B' were identified by a combination of manual Edman degradation and high performance liquid chromatography (HPLC) on a Shodex ODSpak F-511A column (4.6 $\times$ 250 mm, Showa Denko Co., Tokyo). The lyophilized prokallikrein B (0.262 A_{280} eq.) and kallikrein B' (0.340 A_{280} eq.) were used. The manual Edman degradations were performed by the three-stage method of Edman as described by Sauer *et al.*⁸⁾ A 20 μ l aliquot of the sample solution dissolved in 0.2 ml of 0.01 M sodium acetate, pH 5.0, was applied to a Shodex ODSpak F-511A column and developed with the same sodium acetate solution containing 32.5% acetonitrile at a flow rate of 1 ml per min at 70 °C. The retention times of the PTH-amino acids were automatically recorded on an autorecorder by measuring the absorbance at 269 nm.

Results

Purification of Prokallikreins A and B

All of the following procedures were carried out at 0–2 °C. Porcine pancreas (500 g) was minced with a meat grinder and 1.5 l of ammonium sulfate solution (electric conductivity 5 mS/cm), pH 6.0, containing benzamidine (final concentration 10 mM), N-ethylmaleimide (10 mM), ethylenediaminetetraacetic acid disodium salt (EDTA·2Na) (10 mM) and SBTI (1.5 g) was added to it. The pH was adjusted to 4.8 with 1 N HCl, and the mixture was stirred for 3 h. Then, it was centrifuged for 30 min at 7000 rpm and the supernatant was obtained. Solid ammonium sulfate was added to this supernatant and the precipitate formed between 33 and 80% saturation was collected. The precipitate was dissolved in H₂O (300 ml) containing 6 mg of SBTI and the pH was adjusted to 6.0 with diluted ammonia solution. The solution was dialyzed for 10 h against H₂O. After centrifugation (7000 rpm, 30 min), the clear supernatant was obtained. This solution contained 700 EU of prokallikrein. The electric conductivity and the pH of the supernatant were adjusted to 5.0 mS/cm and 6.0, respectively, and the solution was applied to a carboxymethyl (CM)-cellulose column (4.5 $\times$ 30 cm) equilibrated with 5.0 mS/cm of ammonium acetate, pH 6.0. Non-adsorbed substances were then directly applied to a DEAE-Sepharose CL-6B column and the substances adsorbed on the column were eluted (Fig. 1). As shown in Fig. 1, prokallikrein A (fraction No. 90–118) and prokallikrein B (fraction No. 60–89) were eluted before the active kallikrein. Prokallikreins A and B fractions were separately pooled and then immunoaffinity chromatographies were carried out. As shown in Fig. 2, prokallikreins were adsorbed on the column and eluted with diluted HCl (pH 2.8). The pooled prokallikreins A and B solutions were concentrated and separately gel-filtered on a Sephacryl S-200 column. Prokallikreins A and B were each eluted as a single peak. The separately pooled prokallikreins A and B fractions obtained after the gel filtrations had specific activities of 75.0 and 79.4 EU/ A_{280} , respectively. However, these prokallikreins A and B preparations contained 10 and 36.3% of active form,

Fig. 1. Elution Profiles of Porcine Pancreatic Prokallikreins A and B from a DEAE-Sephacryl CL-6B Column

Non-adsorbed fractions from a CM-cellulose column were directly applied to a DEAE-Sephacryl CL-6B column (3.0 × 25 cm) equilibrated with 5.0 mU/cm ammonium acetate, pH 6.0. The column was washed with 500 ml of the same solution and further with 10.0 mU/cm ammonium acetate, pH 6.0, until the absorbance at 280 nm of the eluate was less than 0.1. Then, linear gradient elution with 10.0 to 35.0 mU/cm ammonium acetate, pH 6.0 (total 1600 ml) was carried out. — in the figure shows the fractions pooled for prokallikreins A and B.

Fig. 2. Immunoaffinity Chromatographies of Porcine Pancreatic Prokallikreins A (I) and B (II)

Porcine pancreatic prokallikrein A fractions pooled in Fig. 1 were dialyzed against 10.0 mU/cm ammonium acetate, pH 6.0, and concentrated to 12.3 ml. The concentrate was again dialyzed against 0.01 M phosphate buffer, pH 7.4, containing 0.2 M NaCl. A half of the dialysate was applied to an anti-porcine pancreatic kallikrein B antibody-immobilized Sepharose 4B column (2.6 × 10.0 cm), which was allowed to stand for 10 h at 4°C. The column was washed with about 200 ml of the same buffer. Then, the column was washed with 0.01 M phosphate buffer, pH 7.4, containing both 1.0 M NaCl and 0.1% Triton X-100 (a), 0.001 M phosphate buffer, pH 7.4 (b) and diluted HCl, pH 2.8 (c).

Prokallikrein B fractions pooled in Fig. 1 were also concentrated to 25.0 ml and the same procedures as mentioned above were carried out.

TABLE I. Summary of the Purification of Porcine Pancreatic Prokallikreins A and B

Purification step	Protein (A_{280})	Prokallikrein (EU) ^{a)}	Recovery (%)	S.A. ^{d)} (EU/ A_{280})	P.F. ^{e)}
Dialysate of 33—80% $(\text{NH}_4)_2\text{SO}_4$ precipitate	10271	700 ^{b)}	100	0.068	1
DEAE-Sephacryl CL-6B chromatography	A) 174 B) 168	195 (2.6) ^{c)} 263 (0.0)	27.9 37.6	1.12 1.57	16 23
Immunoaffinity chromatography	A) 0.10 B) 1.14	3.7 (13.5) 55.9 (24.5)	0.5 8.0	37.0 49.0	544 721
Sephacryl S-200 gel filtration	A) 0.04 B) 0.17	3.0 (10.0) 13.5 (36.3)	0.4 1.9	75.0 79.4	1103 1168

a) Assayed after treatment with trypsin. b) The total kallikrein (after treatment with trypsin) in the dialysate of 33—80% $(\text{NH}_4)_2\text{SO}_4$ precipitate was 2509 EU and the amount of active form of kallikrein (before treatment with trypsin) was 1809 EU. Thus, the amount of prokallikrein in this dialysate was 700 EU. Active form of kallikrein in this dialysate was separated from prokallikrein by the next anion-exchange chromatography. c) Contents of the active form of kallikrein (EU, untreated/EU, treated with trypsin × 100). d) Specific activity. e) Purification factor.

respectively, which were spontaneously generated from prokallikreins during these purification procedures because we had pooled prokallikrein fractions which contained almost no active kallikrein from the DEAE-Sephacryl CL-6B chromatography (Fig. 1). Table I summarizes the purification of prokallikreins A and B mentioned above.

Fig. 3. SDS-Polyacrylamide Gel Electrophoresis of Prokallikrein B and Kallikrein B before and after Reduction with 2-ME

- Prokallikrein B (0.108 EU), after the reduction.
- Prokallikrein B (0.320 EU), after the reduction.
- Kallikrein B (0.220 EU), before the reduction.
- Prokallikrein B (0.108 EU), before the reduction.
- Prokallikrein B (0.324 EU), before the reduction.

TABLE II. Manual Edman Degradation of Prokallikrein B and Kallikrein B'

Cycle	Prokallikrein B		Kallikrein B''	
	Residue	Yield ^(a)	Residue	Yield ^(a)
1	Ala	873	Ile	4700
	Ile	496		
2	Pro	192	Ile	2650
	Ile	146		
3	Pro	60	Gly	928
4			Gly	395

a) pmol.

Fig. 4. Amino Acid Sequences Near the Pro-Region of Kallikreins from Various Origins

The N-terminal amino acid sequence of porcine pancreatic prokallikrein, H-Ala-Pro-Pro-, obtained in the present study was added to the sequence of A-chain of porcine pancreatic kallikrein reported by Fiedler *et al.*⁹⁾ The arrows show the predicted cleavage points for pre-pro-porcine pancreatic kallikrein.

Figure 3 shows the results of SDS-polyacrylamide gel electrophoresis of prokallikrein B before and after reduction with 2-ME. Before the reduction with 2-ME, prokallikrein B showed a broad band (Fig. 3d and e) which migrated slightly more slowly than kallikrein B (Fig. 3c). Prokallikrein B also showed a single band after the reduction with 2-ME (Fig. 3a and b).

N-Terminal Amino Acid Sequence

When kallikrein B'' was subjected to manual Edman degradation, PTH-Ile, -Ile, -Gly and -Gly were identified at the first 4 cycles as PTH-amino acids (no contaminating PTH-amino acid could be observed at each cycle) (Table II). Thus, the N-terminal amino acid sequence of kallikrein B'' was identified as H-Ile-Ile-Gly-Gly-. On the other hand, when prokallikrein B was subjected to the manual Edman degradations, PTH-Ala and -Ile were identified at the 1st cycle of degradation. PTH-Pro and -Ile were identified at the 2nd cycle, and PTH-Pro was identified at the 3rd cycle. Thus, the N-terminal amino acid sequence of prokallikrein B might be H-Ala-Pro-Pro- (see Discussion).

Discussion

It is well known that porcine pancreatic kallikrein obtained from autolyzed pancreas is usually separated into two main components, *i.e.*, kallikreins A and B, by anion-exchange chromatographies. These kallikreins are β -kallikrein. On the other hand, kallikreins A'' and B'' generated from prokallikreins A and B by the action of trypsin are α -kallikrein. Besides these kallikreins, kallikreins A' and B', which are kallikreins spontaneously generated during the purification of prokallikreins, were also reported.⁹⁾ These kallikreins are also α -kallikrein. The specific activities of the purified kallikreins mentioned above are 90–110 EU/ A_{280} .²⁾ Our final prokallikreins A and B preparations had specific activities of 75.0 and 79.4 EU/ A_{280} , respectively, when assayed after activation with trypsin. Although these values were slightly lower than those mentioned above, the high purities of these preparations were confirmed by the SDS-polyacrylamide gel electrophoresis. However, a broad protein band was observed, especially when a high dose of prokallikrein B was subjected to electrophoresis (Fig. 3e). Our present final prokallikrein B preparation contained about 36% of active form (Table I). Therefore, the broad band can be explained by the coexisting active form kallikrein, as judged from the migration length of kallikrein B (Fig. 3c) and also from the results obtained in our detailed comparison of various kallikreins generated from prokallikreins.²⁾

The N-terminal amino acid sequence of kallikrein B'' was determined to be H-Ile-Ile-Gly-Gly-. This sequence is identical with that of A-chain of kallikrein B.⁹⁾ On the other hand, we observed (Ala, Ile) and (Pro, Ile) on the 1st and 2nd cycles of Edman degradation, respectively. Figure 4 summarizes the already known near pro-region structures of various kallikreins which were obtained from analyses of their messenger ribonucleic acid and complementary deoxyribonucleic acid or direct polypeptide chain analyses. Judging from these sequences and our present results, the N-terminal amino acid sequence of prokallikrein B might be H-Ala-Pro-Pro-; the Ile observed at the 1st and 2nd cycles was considered to be derived from active kallikrein coexisting in the prokallikrein B preparation. We could not detect the amino acid sequence of prokallikrein B after the 3rd cycle since the amount of prokallikrein B preparation was insufficient for the manual Edman degradation. However, as shown in Fig. 4, the pro-region amino acid sequences of kallikreins from various origins are extremely similar to each other. Thus, the present study indicated that a peptide consisting of 7 amino acids would be released when porcine pancreatic prokallikrein is activated, although it remains to be determined whether or not trypsin is the true physiological activator of prokallikrein in the body.

Acknowledgements We would like to thank Dr. Tadashi Yasuhara, Institute for Medical and Dental Engineering, Tokyo Medical and Dental University, and Prof. Terumi Nakajima, Faculty of Pharmaceutical Sciences, University of Tokyo, for valuable advice and discussions on the manual Edman degradation. This work was supported in part by Grants-in-Aids for Scientific Research from the Ministry of Education, Science and Culture of Japan, from Toray Science Foundation and from the Ryoichi Naito Foundation for Medical Research.

References

- 1) F. Fiedler and C. Hirschauer, *Hoppe-Seyler's Z. Physiol. Chem.*, **362**, 1209 (1981).
- 2) K. Kizuki, H. Takiguchi, M. Kamada, M. Ikekita and H. Moriya, *Chem. Pharm. Bull.*, **32**, 3662 (1984).
- 3) K. Kizuki, M. Ikekita, Y. Shimamoto and H. Moriya, *Chem. Pharm. Bull.*, **30**, 2561 (1982).
- 4) K. Kizuki, M. Kamada, M. Ikekita and H. Moriya, *Chem. Pharm. Bull.*, **30**, 3354 (1982).
- 5) M. Ikekita, H. Moriya, S. Ozawa and K. Kizuki, *Chem. Pharm. Bull.*, **29**, 545 (1981).
- 6) P. Cuatrecasas, *J. Biol. Chem.*, **245**, 3059 (1970).
- 7) U. K. Laemmli, *Nature (London)*, **227**, 680 (1970).
- 8) R. T. Sauer, H. D. Niall, M. L. Hogan, H. T. Keutmann, J. L. H. O'Riordan and J. T. Potts, Jr., *Biochemistry*, **13**, 1994 (1974).
- 9) F. Fiedler, E. Fink, H. Tschesche and H. Fritz, *Methods in Enzymology*, **80**, 493 (1981).
- 10) G. H. Swift, J. C. Dagorn, P. L. Ashley, S. W. Cummings and R. J. MacDonald, *Proc. Natl. Acad. Sci. U.S.A.*, **79**, 7263 (1982).
- 11) D. Fukushima, N. Kitamura and S. Nakanishi, *Biochemistry*, **24**, 8037 (1985).
- 12) S. Takahashi, A. Irie, Y. Katayama, K. Ito and Y. Miyake, *J. Biochem. (Tokyo)*, **99**, 989 (1986).
- 13) F. Lottspeich, R. Geiger, A. Henschen and C. Kutzbach, *Hoppe-Seyler's Z. Physiol. Chem.*, **360**, 1947 (1979).
- 14) A. J. Mason, B. A. Evans, D. R. Cox, J. Shine and R. I. Richards, *Nature (London)*, **303**, 300 (1983).